ADHD: FDA Approves New CNS Drug Simtriyo for Adults and Children

The FDA has granted approval to SIMTRIYO, a new medication intended for the treatment of attention deficit hyperactivity disorder (ADHD). This drug, developed by Otsuka Pharmaceutical, is a daily extended-relief tablet for both adults and children 6 years and older who weigh at least 44 pounds. It represents the first norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) available for this purpose.

Clinical trials conducted across adult and pediatric populations showed that patients experienced significant improvements in ADHD symptoms compared to those who received a placebo. Researchers observed outcomes in four phase 3 clinical trials, with additional data from a phase 3b study focused on adults with ADHD and comorbid anxiety. The manufacturer expects the medication to be available via prescription later this year following final scheduling determinations by the Drug Enforcement Administration.

While medical professionals recognize the value of adding a new tool to existing ADHD treatment protocols, they maintain a cautious outlook. The drug carries a boxed label warning regarding potential risks for suicidal ideation in pediatric patients, as well as warnings concerning abuse and addiction. Experts note that while medication acts as a starting point for managing symptoms, patients must often combine medical treatment with behavioral therapies to achieve long-term success.

Healthcare providers like Dr. Daniel Ganjian and Dr. Max Wiznitzer stated they intend to use SIMTRIYO primarily as a secondary option for patients who have not responded to current stimulant or nonstimulant medications. They plan to monitor clinical performance closely as the drug enters the market. For families and adults navigating ADHD, the focus remains on a team-based approach that includes behavioral support, consistent organization, and medical guidance.